← Back to Search

Natural Extract

PediaBerry for Hemangioma (Pediaberry Trial)

Phase < 1
Waitlist Available
Led By Gayle Gordillo, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 month treatment period

Summary

This trial tests PediaBerry™, a powdered mix of berry extracts, on infants with hemangiomas. The treatment is applied on the skin and given orally to help reduce these benign growths.

Eligible Conditions
  • Hemangioma
  • Placental Chorioangioma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 month treatment period
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 month treatment period for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Decreased Hemangioma Size
Secondary study objectives
Decreased urinary micro RNA 126 levels

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Pediaberry groupExperimental Treatment1 Intervention
PediaBerry™ is a proprietary blend powdered berry extracts
Group II: PlaceboPlacebo Group1 Intervention
Placebo: powdered sugar plus McCormick Color from Nature Food Colors Berry and Sky Blue powdered food color (https://www.mccormick.com/spices-and-flavors/extracts-and-food-colors/food-colors/color-from-nature-assorted-food-color ).

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
1,035 Previous Clinical Trials
1,218,967 Total Patients Enrolled
Gayle GordilloLead Sponsor
5 Previous Clinical Trials
134 Total Patients Enrolled
1 Trials studying Hemangioma
68 Patients Enrolled for Hemangioma
National Institute of General Medical Sciences (NIGMS)NIH
289 Previous Clinical Trials
248,787 Total Patients Enrolled

Media Library

PediaBerry (Natural Extract) Clinical Trial Eligibility Overview. Trial Name: NCT04020419 — Phase < 1
Hemangioma Research Study Groups: Pediaberry group, Placebo
Hemangioma Clinical Trial 2023: PediaBerry Highlights & Side Effects. Trial Name: NCT04020419 — Phase < 1
PediaBerry (Natural Extract) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04020419 — Phase < 1
~2 spots leftby Nov 2025